Glumetinib, a MET inhibitor indicated for the treatment of patients with specific non-small cell lung cancer, requires dosage adjustments based on the physiological status of special populations. These populations primarily include pregnant women, lactating women, patients with hepatic or renal impairment, children, and the elderly. Specific medication use must strictly follow the doctor’s assessment, and self-adjustment of dosage or discontinuation of treatment is prohibited.
Precautions for Medication in Special Populations
1. Pregnant and Lactating Women
Contraindicated in pregnancy: Animal studies have demonstrated that glumetinib exhibits embryotoxicity and may cause severe harm to the fetus. Effective contraceptive measures should be adopted during treatment, and contraception must be continued for at least 3 months after the end of therapy.
Contraindicated during lactation: There are no available data regarding whether the drug is excreted in human milk. It is recommended to discontinue breastfeeding during treatment and for 1 week after treatment completion.
2. Pediatric and Adolescent Patients
Insufficient safety data: No clinical studies have been conducted in populations under 18 years of age, and the use of glumetinib is not recommended for this group.
3. Geriatric Patients (≥ 65 Years Old)
Use with caution: Geriatric patients may be more sensitive to drug metabolism and adverse reactions. Close monitoring of hepatic and renal function as well as adverse events (e.g., edema, fatigue) is required.
4. Patients with Hepatic or Renal Impairment
Hepatic impairment: Dose reduction is necessary for patients with moderate to severe hepatic dysfunction (Child-Pugh Class B/C). Specific adjustments must be determined based on the doctor’s assessment.
Renal impairment: For patients with mild to moderate renal impairment (eGFR ≥ 30 mL/min), dosage adjustment is generally not required, but regular monitoring is essential. Data in patients with severe renal impairment are limited, and glumetinib should be used with caution in this population.
5. Hypersensitivity and Drug Interactions
Contraindicated in hypersensitivity: Patients with a known hypersensitivity to any component of the drug are prohibited from using glumetinib.
Drug interactions: Glumetinib may be affected by CYP3A enzyme inhibitors or inducers. Concomitant use with potent CYP3A inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin) should be avoided. If co-administration is deemed necessary, dosage adjustment may be required.
Principles of Medication
Strictly follow medical advice
Glumetinib is a prescription-only medication. Treatment regimens must be individualized based on the patient’s condition (e.g., gene testing results, comorbidities).
Regular monitoring
During treatment, liver function, blood routine, and other relevant tests should be performed every 2–4 weeks. Immediate medical attention is required if symptoms such as dyspnea or severe skin rash occur.
Full disclosure of medical history
Patients with special health conditions (e.g., organ transplantation, immunodeficiency) must inform their doctors in advance to comprehensively evaluate the benefits and risks of treatment.
